BY CHRISTIAN BUNDGAARD
-
Bavarian Nordic reports decline in operating profit and bottom line in 2024
Revenue was already known prior to the publication of the annual report on Wednesday morning.
-
Leo Pharma outlines IPO plans for 2026
The Danish dermatology team is planning for an IPO in 2026. The business’s brand-new head of study discusses the approaching financial investments in possible brand-new medic…
-
Gubra is pleased to partner with Abbvie: Our drug starts their obesity pipeline
According to Chief Executive Officer Henrik Blou, Gubra’s excessive weight prospect Gubamy is an excellent suitable for Abbvie, which has nothing else excessive weight posses…
-
Gubra turns to women’s health: “We’re not just an obesity company”
In its annual report for 2024, Gubra has launched a technique of recent ”flagship areas”. The primary shall be girls’s ailments, which based on the chief exec is attracting numerou…
-
Novo Holdings ranks high on active biotech investors list
Novo Holdings has actually jointly spent 10s of billions of bucks in the race in 2024, according to sector media Endpoints.
-
Former Novo Nordisk partner sold for USD 29m
The arrangement with Carlyle and SK Resources Allies was the “just practical remedy to develop produce worth for investors,” the firm creates.
-
Boston Scientific raising EUR 1.5bn for M&A
The cash will certainly be increased by the issuance of 2 company bonds.
-
ALK reaches DKK 1bn in operating profit – tablet sales grow 24%
The allergy firm considerably improved its profitability in 2024.
-
Pfizer boss praises Trump ahead of White House meeting
A variety of huge pharma leaders will certainly quickly meet Donald Trump. Pfizer’s chief executive officer has actually currently shared his appreciation.
-
Pfizer boss praises Trump ahead of White House meeting
A number of big pharma leaders will soon meet with Donald Trump. Pfizer’s CEO has already expressed his praise.
